Erfe - clinical significance

• ERFE can predict mortality in patients with CKD and heart failure

• ERFE could be a therapeutic target for iron loading anemias

• ERFE levels may detect the abuse of erythropoiesis stimulating agents (ESAs) in the anti-doping field


Sarah Appleby, Janice Chew-Harris, Richard Troughton, Mark Richards, Christopher Pemberton. Erythroferrone Can Diagnose Acute Decompensated Heart Failure in Patients Presenting With Breathlessness. Circulation.
2018 Nov; 138: A11094.

Murphy D, McCulloch CE, Lin F, Banerjee T, Bragg-Gresham JL, Eberhardt MS, Morgenstern H, Pavkov ME, Saran R, Powe NR, Hsu CY. Trends in Prevalence of Chronic Kidney Disease in the United States. Ann Intern Med. 2016 Oct 4;165(7):473-481.

Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–528.

Arezes J, Foy N, McHugh K, Quinkert D, Benard S, Sawant A, Frost JN, Armitage AE, Pasricha SR, Lim PJ, Tam MS, Lavallie E, Pittman DD, Cunningham O, Lambert M, Murphy JE, Draper SJ, Jasuja R, Drakesmith H. Antibodies against the erythroferrone N-terminal domain prevent hepcidin suppression and ameliorate murine thalassemia. Blood. 2020 Feb 20;135(8):547-557.

Ramirez Cuevas K, Schobinger C, Gottardo E, Voss SC, Kuuranne T, Tissot JD, Favrat B, Townsend N, Leuenberger N. Erythroferrone as a sensitive biomarker to detect stimulation of erythropoiesis. Drug Test Anal. 2020 Feb;12(2):261-267.